These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 28954880)

  • 41. Effect of metformin-containing antidiabetic regimens on all-cause mortality in veterans with type 2 diabetes mellitus.
    Gosmanova EO; Canada RB; Mangold TA; Rawls WN; Wall BM
    Am J Med Sci; 2008 Sep; 336(3):241-7. PubMed ID: 18794619
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Sulfonylurea and Cancer Risk Among Patients With Type 2 Diabetes: A Population-Based Cohort Study.
    Zhao H; Liu Z; Zhuo L; Shen P; Lin H; Sun Y; Zhan S
    Front Endocrinol (Lausanne); 2022; 13():874344. PubMed ID: 35846337
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus.
    Ou SM; Shih CJ; Chao PW; Chu H; Kuo SC; Lee YJ; Wang SJ; Yang CY; Lin CC; Chen TJ; Tarng DC; Li SY; Chen YT
    Ann Intern Med; 2015 Nov; 163(9):663-72. PubMed ID: 26457538
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Metformin versus sulphonylureas for new onset atrial fibrillation and stroke in type 2 diabetes mellitus: a population-based study.
    Zhou J; Zhang G; Chang C; Chou OHI; Lee S; Leung KSK; Wong WT; Liu T; Wai AKC; Cheng SH; Zhang Q; Tse G
    Acta Diabetol; 2022 May; 59(5):697-709. PubMed ID: 35112189
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Initial metformin or sulphonylurea exposure and cancer occurrence among patients with type 2 diabetes mellitus.
    Qiu H; Rhoads GG; Berlin JA; Marcella SW; Demissie K
    Diabetes Obes Metab; 2013 Apr; 15(4):349-57. PubMed ID: 23137378
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Metformin does not affect cancer risk: a cohort study in the U.K. Clinical Practice Research Datalink analyzed like an intention-to-treat trial.
    Tsilidis KK; Capothanassi D; Allen NE; Rizos EC; Lopez DS; van Veldhoven K; Sacerdote C; Ashby D; Vineis P; Tzoulaki I; Ioannidis JP
    Diabetes Care; 2014 Sep; 37(9):2522-32. PubMed ID: 24898303
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Association of Metformin Use With Risk of Lactic Acidosis Across the Range of Kidney Function: A Community-Based Cohort Study.
    Lazarus B; Wu A; Shin JI; Sang Y; Alexander GC; Secora A; Inker LA; Coresh J; Chang AR; Grams ME
    JAMA Intern Med; 2018 Jul; 178(7):903-910. PubMed ID: 29868840
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Sulfonylurea Is Associated With Higher Risks of Ventricular Arrhythmia or Sudden Cardiac Death Compared With Metformin: A Population-Based Cohort Study.
    Lee TTL; Hui JMH; Lee YHA; Satti DI; Shum YKL; Kiu PTH; Wai AKC; Liu T; Wong WT; Chan JSK; Cheung BMY; Wong ICK; Cheng SH; Tse G
    J Am Heart Assoc; 2022 Sep; 11(18):e026289. PubMed ID: 36102222
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Kidney function decline in metformin versus sulfonylurea initiators: assessment of time-dependent contribution of weight, blood pressure, and glycemic control.
    Hung AM; Roumie CL; Greevy RA; Liu X; Grijalva CG; Murff HJ; Griffin MR
    Pharmacoepidemiol Drug Saf; 2013 Jun; 22(6):623-31. PubMed ID: 23592561
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Different antidiabetic regimens and the development of renal dysfunction in US Veterans with type 2 diabetes mellitus.
    Gosmanova EO; Canada RB; Wan J; Mangold TA; Wall BM
    J Investig Med; 2012 Oct; 60(7):1009-14. PubMed ID: 22801248
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Incident dementia risk among patients with type 2 diabetes receiving metformin versus alternative oral glucose-lowering therapy: an observational cohort study using UK primary healthcare records.
    Doran W; Tunnicliffe L; Muzambi R; Rentsch CT; Bhaskaran K; Smeeth L; Brayne C; Williams DM; Chaturvedi N; Eastwood SV; Dunachie SJ; Mathur R; Warren-Gash C
    BMJ Open Diabetes Res Care; 2024 Jan; 12(1):. PubMed ID: 38272537
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Safety of add-on sulfonylurea therapy in patients with type 2 diabetes using metformin: a population-based real-world study.
    Hougen I; Whitlock RH; Komenda P; Rigatto C; Clemens KK; Tangri N
    BMJ Open Diabetes Res Care; 2021 Dec; 9(2):. PubMed ID: 34969692
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Predictors of insulin initiation in metformin and sulfonylurea users in primary care practices: the role of kidney function.
    Kostev K; Dippel FW; Rathmann W
    J Diabetes Sci Technol; 2014 Sep; 8(5):1023-8. PubMed ID: 24876433
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Secondary failure rates associated with metformin and sulfonylurea therapy for type 2 diabetes mellitus.
    Eurich DT; Simpson SH; Majumdar SR; Johnson JA
    Pharmacotherapy; 2005 Jun; 25(6):810-6. PubMed ID: 15927899
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The effect of incident antidiabetic regimens on lipid profiles in veterans with type 2 diabetes: a retrospective cohort.
    Roumie CL; Huizinga MM; Liu X; Greevy RA; Grijalva CG; Murff HJ; Hung AM; Griffin MR
    Pharmacoepidemiol Drug Saf; 2011 Jan; 20(1):36-44. PubMed ID: 21182152
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cardiovascular safety of metformin and sulfonylureas in patients with different cardiac risk profiles.
    Wurm R; Resl M; Neuhold S; Prager R; Brath H; Francesconi C; Vila G; Strunk G; Clodi M; Luger A; Pacher R; Hülsmann M
    Heart; 2016 Oct; 102(19):1544-51. PubMed ID: 27226327
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cardiovascular safety of glucose-lowering agents as add-on medication to metformin treatment in type 2 diabetes: report from the Swedish National Diabetes Register.
    Ekström N; Svensson AM; Miftaraj M; Franzén S; Zethelius B; Eliasson B; Gudbjörnsdottir S
    Diabetes Obes Metab; 2016 Oct; 18(10):990-8. PubMed ID: 27282621
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Metformin use and incidence cancer risk: evidence for a selective protective effect against liver cancer.
    Murff HJ; Roumie CL; Greevy RA; Hackstadt AJ; McGowan LED; Hung AM; Grijalva CG; Griffin MR
    Cancer Causes Control; 2018 Sep; 29(9):823-832. PubMed ID: 30022336
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Sulfonylureas and risk of falls and fractures among nursing home residents with type 2 diabetes mellitus.
    Lapane KL; Jesdale BM; Dubé CE; Pimentel CB; Rajpathak SN
    Diabetes Res Clin Pract; 2015 Aug; 109(2):411-9. PubMed ID: 26008723
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The risk of coronary heart disease in type 2 diabetic patients exposed to thiazolidinediones compared to metformin and sulfonylurea therapy.
    Johannes CB; Koro CE; Quinn SG; Cutone JA; Seeger JD
    Pharmacoepidemiol Drug Saf; 2007 May; 16(5):504-12. PubMed ID: 17245800
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.